Logo image
Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis
Journal article   Peer reviewed

Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis

Michael N. Mavros, Li Xu, Hadia Maqsood, Faiz Gani, Aslam Ejaz, Gaya Spolverato, Waddah B. Al-Refaie, Steven M. Frank and Timothy M. Pawlik
Annals of Surgical Oncology, Vol.22(13)
2015

Abstract

Blood Transfusion Female Humans Male Neoplasm Staging Pancreatectomy Pancreatic Neoplasms Perioperative Care Prognosis Survival Rate bile duct carcinoma blood transfusion cancer prognosis cancer survival exocrine tumor of pancreas human meta analysis outcome assessment overall survival pancreas adenocarcinoma pancreas cancer pancreas carcinoma pancreas resection pancreaticoduodenectomy perioperative blood transfusion perioperative period randomized controlled trial (topic) Review systematic review cancer staging female male mortality pancreas resection Pancreatic Neoplasms pathology prognosis survival rate
Background: Perioperative blood transfusion (PBT) is common in pancreatic surgery. Recent studies have suggested that PBT may be associated with worse long-term outcomes. Methods: A systematic review and meta-analysis of studies comparing long-term clinical outcomes of cancer patients undergoing curative-intent pancreatic surgery with regard to occurrence of PBT was performed. Results: A total of 23 studies (4339 patients) were included in the systematic review, and 19 studies (3646 patients) were included in the meta-analysis. Nearly half (45.8 %) of all patients were female (range 25–60 %), and median age ranged from 59 to 72 years. About half (46.5 %, range 19–72 %) of the patients were transfused. Most had pancreatic ductal adenocarcinoma (69.5 %), while others had ampullary carcinoma (15.0 %), cholangiocarcinoma (7.4 %), or exocrine tumors of pancreas (8.1 %). Most (91.1 %) underwent pancreaticoduodenectomy, while the remaining patients underwent a total or distal pancreatectomy. The 5-year overall survival for all patients ranged from 0 to 65 %. Thirteen and nine of 19 studies reported a detrimental effect of PBT on survival on univariable and multivariable analysis, respectively. Overall, PBT was associated with shorter overall survival (pooled odds ratio 2.43, 95 % confidence interval 1.90–3.10); this finding was reproduced in sensitivity analysis. Conclusions: Patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery. Further research should focus on implementing guidelines for and discerning factors associated with the poor outcomes after PBT. © 2015, Society of Surgical Oncology.

Metrics

10 Record Views

Details

Logo image